Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226093 | 1.00 | KMT2A (0.38) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL2533038 | 1.00 | KMT2A (0.38) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL2535254 | 1.00 | KMT2A (0.38) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL2533656 | 0.91 | KMT2A (0.36) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL2535446 | 0.91 | KMT2A (0.36) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL2533653 | 0.91 | KMT2A (0.36) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL1480821 | 0.87 | KMT2A (0.40) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL1480822 | 0.87 | KMT2A (0.40) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL1481301 | 0.87 | KMT2A (0.40) | KMT2AFABP5PARP1FABP7GBA1 | |
| SCHEMBL1480114 | 0.85 | KMT2A (0.38) | KMT2AFABP5PARP1FABP7GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046796-B1 | TETRAHYDROFURO [3, 2 -B]PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-8039641-B2 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| US-8039641-B2 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2011-10-18 | — | — | US | disclosed |
| US-7803803-B2 | Tetrahydrofuro[3,2-B] pyrrol-3-ones as cathepsin K inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803803-B2 | Tetrahydrofuro[3,2-B] pyrrol-3-ones as cathepsin K inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803803-B2 | Tetrahydrofuro[3,2-B] pyrrol-3-ones as cathepsin K inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-7799791-B2 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2008007132-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007114-A1 | TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007112-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197817-A1 | Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors | CTSS, CTSK, TMPRSS6 | KMT2A 4105/4885FABP5 3363/4885PARP1 3492/4885 |
| US-20090186831-A1 | Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases | TMPRSS6, CCR6, MMP8 | KMT2A 4223/4885FABP5 3806/4885PARP1 3092/4885 |
| US-20090192322-A1 | Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates | CYP4F8, CYP2C8, AVPR1B | KMT2A 3122/4885FABP5 3039/4885PARP1 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.